贝伐珠单抗联合化疗在结直肠癌靶向治疗中的临床应用观察

Clinical application of bevacizumab combined with chemotherapy in targeted treatment of colorectal cancer

目的探讨贝伐珠单抗联合化疗在结直肠癌靶向治疗中的应用效果。方法回顾性分析广州白云山医院2022年6月至2023年6月收治的68例结直肠癌患者的临床资料,根据治疗方案的不同分为对照组(化疗,33例)与研究组(贝伐珠单抗+化疗,35例),比较两组患者的疗效、肿瘤标志物水平及不良反应发生情况。结果研究组患者的疾病控制率为94.29%,高于对照组(72.73%),差异有显著性(P<0.05)。治疗前,两组糖类抗原(carbohydrate antigen,CA)19-9、CA 72-4及癌胚抗原水平无显著差异(P>0.05);治疗后,研究组患者的CA 19-9、CA 72-4及癌胚抗原水平均低于对照组差异有显著性(P<0.05)。两组患者不良反应总发生率无显著差异(P>0.05)。结论贝伐珠单抗联合化疗可显著提升结直肠癌患者的疾病控制率,降低机体肿瘤标志物水平,且不良反应风险未见增长。

Objective To explore the application effect of bevacizumab combined with chemotherapy in targeted therapy for colorectal cancer.Method A retrospective analysis was conducted on the clinical data of 68 patients with colorectal cancer admitted to Guangzhou Baiyunshan Hospital from June 2022 to June 2023.They were divided into a control group(chemotherapy,33 cases)and a study group(bevacizumab+chemotherapy,35 cases)based on diff erent treatment plans.The therapeutic effi cacy,tumor marker levels,and incidence of adverse reactions were compared between the two groups of patients.Result The disease control rate of the study group patients was 94.29%,higher than that of the control group(72.73%),with a significant difference(P<0.05).Before treatment,there was no signifi cant diff erence in the levels of carbohydrate antigen(CA)19-9,CA 72-4,and carcinoembryonic antigen between the two groups(P>0.05);After treatment,the average levels of CA 19-9,CA 72-4,and carcinoembryonic antigen in the study group were signifi cantly lower than those in the control group(P<0.05).There was no signifi cant diff erence in the total incidence of adverse reactions between the two groups of patients(P>0.05).Conclusion Bevacizumab combined with chemotherapy can signifi cantly improve the disease control rate of colorectal cancer patients,reduce the level of tumor markers in the body,and there is no increase in the risk of adverse reactions.